SPPAM
PCRX icon

Summit Partners Public Asset Management’s Pacira BioSciences PCRX Stock Holding History

Summit Partners Public Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-226,276
Closed -$13.7M – 145
2021
Q2 		$13.7M Buy
+226,276
New +$14.3M 0.49% 71

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Summit Partners Public Asset Management's PCRX Position: Q3 2021 in Review

Summit Partners Public Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2021, closing a stake of 226,276 shares — an estimated $13.7M sold.

Summit Partners Public Asset Management first reported a position in PCRX in Q2 2021 and held it in 1 quarter. The position peaked at $13.7M in Q2 2021. 259 funds tracked by Wall St. Rank hold PCRX as of Q3 2021.

  • Summit Partners Public Asset Management reported no remaining Pacira BioSciences position as of Q3 2021 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 226,276 Pacira BioSciences shares in Q3 2021, an estimated $13.7M.
  • Summit Partners Public Asset Management first reported a position in Pacira BioSciences in Q2 2021 and held it in 1 quarter.
  • Summit Partners Public Asset Management's Pacira BioSciences position peaked at $13.7M in Q2 2021.
  • 259 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2021.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.